DRUG
Pasireotide
Pasireotide 600 μg or 900 μg was administered as an SC injection.
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Status
Completed
Phase
Phase 2
Enrollment
19
Locations
8
Results
Posted
Publications
1
Study summary
What the protocol is testing.
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study assessed the long-term safety and efficacy of pasireotide in participants with Cushing's disease.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Sep 15, 2005
Study start
Aug 13, 2004
Primary completion
Jul 8, 2013
Study completion
Jul 8, 2013
Results posted
Jun 2, 2021
Registry updated
Jun 2, 2021
Outcomes
What the study measures.
Primary outcomes
Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits
Time frame · Month 6
A participant was considered a responder if the mean UFC from the two 24-hour urine samples collected at Month 6 was within normal limits. The normal range for UFC is 55 to 276 nmol/day.
Change From Baseline in Mean Urinary Free Cortisol (UFC)
Time frame · Core Baseline, Days 14/15 (Core study), Months 6, 12, 24 and 102
24-hour urine samples were collected to obtain mean UFC measurements. A negative mean change from baseline indicates improvement.
Secondary outcomes
Number of Participants Who Had At Least One Adverse Event (AE)
Time frame · Up to approximately 106 months
An AE was any undesirable sign, symptom or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. AEs were assessed according to incident dose group: Pasireotide 1200 μg sc total daily dose (TDD), Pasireotide 1800 μg SC TDD and Pasireotide SC Any Dose. The incident dose for an AE was the last total daily dose administered on or prior to the AE onset date.
Change From Baseline in Serum Cortisol Levels
Time frame · Core Baseline, Day 15 (Core study), Months 6, 12, 24, and Month 105 (end of the study)
Blood samples were withdrawn to obtain the serum cortisol levels. A negative change from baseline indicates improvement.
Plasma Trough Concentrations (Ctrough) of Pasireotide in UFC Responders
Time frame · Day 15 (Core study) and Month 6
Participants with Cushing's disease were considered responders if mean UFC levels from the 24-hour urine collections at Day 15 (Core study) and at extension Month 6, were within normal limits. Ctrough levels of pasireotide were measured at Day 15 of Core study and Month 6.
Change From Baseline in Plasma Adrenocorticotropic Hormone (ACTH) Levels
Time frame · Core Baseline, Day 15 (Core study), Months 6, 12, 24 and Month 105 (end of the study)
Blood samples were withdrawn to obtain the ACTH levels. A negative change from baseline indicates improvement.
Change From Baseline in Gene-expression and Protein in Blood and Urine for Biomarker Development
Time frame · Baseline to end of the study
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Participants who have completed the 15 days of Pasireotide treatment in the CSOM230B2208 study and have achieved normalization of 24-hour urinary free cortisol. Participants who did not achieve normalization of 24 -hour urinary free cortisol may be enrolled if in the opinion of the investigator the participant is getting significant clinical benefits from treatment with Pasireotide . * The participant did not experience any unacceptable adverse events of tolerability issues during the original 15 day treatment. * Female participants of childbearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy or tubal ligation must agree to use barrier contraception throughout the course of the extension study, and for one month after the study has ended. Exclusion Criteria: * Participant who have developed poorly controlled diabetes mellitus as indicated by ketoacidosis or hemoglobin (Hgb) A1C (HgbA1C) \> 10 since starting \[study CSOM230B2208\]. * Participant with persistent alanine aminotransferase (ALT)/ aspartate transaminase (AST) or alkaline phosphatase levels more than 2.5X upper limit of normal (ULN), serum creatinine \> 2.0 X ULN, serum bilirubin \> 2 X ULN. * Participant with abnormal coagulation (Prothrombin time (PT) and partial thromboplastin time (PTT) elevated by 30% above normal limits), white blood cells (WBC) \<3.0x1'000'000'000/L; Hgb \<12.0g/dL for females, Hgb \<13.0g/dL for males; PLT \<100x1'000'000'000/L. Other protocol-defined inclusion / exclusion criteria may apply.
Study locations
8 registered sites.
France · Germany · Italy · United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.
Massachusetts General Hospital
Boston, Massachusetts, United States
Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU.
Portland, Oregon, United States
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Belfast, United Kingdom
Related trials
More studies on Pasireotide.
NCT IDStudyPhase / statusEnrollmentUpdated
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Novartis · Somatostatin Receptor Positive (SSTR+) · Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Phase 3
Recruiting
240
2026-04
A Study of Pasireotide in People With Prolactinoma
Memorial Sloan Kettering Cancer Center · Prolactin-Producing Pituitary Tumor
Phase 2
Recruiting
10
2026-03
Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
RECORDATI GROUP · Pharmacokinetics · Safety
Phase 1
Completed
40
2026-02
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Advanced Accelerator Applications · Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3
Active, not recruiting
226
2026-01
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment
Hospices Civils de Lyon · Enterostomy
Phase 2
Completed
57
2025-12
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
RECORDATI GROUP · Post-Bariatric Hypoglycemia
Phase 2
Active, not recruiting
93
2025-09
Effects of Pasireotide Lar Therapy on Bone Metabolism
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Acromegaly Due to Pituitary Adenoma · Acromegaly
Not applicable
Recruiting
120
2025-09
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Castrate Resistant Prostate Cancer · Chemotherapy Naive Prostate Cancer
Phase 2
Terminated
6
2025-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.